DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

Personalized disease treatment, tailored to an individual’s genetic background, is the future of medicine. Stem cells hold the promise of that objective becoming a reality. A decade ago, the discovery ...

Colossal Biosciences creates technologies for species restoration, critically endangered species protection, and the repopulation of critical ecosystems that support the continuation of life on Earth.

Studies by a team at Stanford University School of Medicine have shown how aged mice regained youthful strength after their muscle stem cells were subjected to a rejuvenating protein treatment and ...

iXCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent ...

Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance ...